. "Purpose: The objective of this study was to evaluate the feasibility, toxicity and efficacy of definitive radiochemotherapy with weekly cisplatin in head and neck cancer in a single institutional setting. Methods: Previously untreated patients with stage II-IV head and neck cancer were included. Radiotherapy consisted of 70 Gy/7 weeks/35 fractions. All patients received concurrent cisplatin 40 mg/m(2) weekly Results: Between 2/2002 and 8/2009, 148 consecutive patients (WHO <= 2, male to female ratio 6/1, median age 56 years) were treated. The mean follow-up was 40 months. Tumors of the oropharynx were the most frequent (46%) and stage IV predominated (80%). Eighty-nine percent of the patients had received the full radiation treatment as planned. Omission of weekly cisplatin occurred frequently, mainly because of hematological toxicity. Only 64% of the patients completed at least 5 cycles of chemotherapy. Grade 3/4 mucosal toxicity developed in 32% of the patients. The late toxicities were acceptable: 74% of the patients were able to eat solid food during the 1st post-treatment year 4 patients were not able to swallow at all during the 1st post-treatment year, requiring thus permanent feeding tube. Five cases of osteora-dionecrosis of the mandible were reported. Three-year overall survival, locoregional control, time to progression and disease free survival were 34, 60, 52 and 29%, respectively. Conclusion: Definitive radiochemotherapy with weekly cisplatin was toxic, with high rate of morbidity and mortality in this patient population. Five weekly cycles of 40 mg/m(2) cisplatin seem to be the dose limit for most patients. Three-year survival was significantly reduced despite the promising high initial response and locoregional control."@en . "1107-0625" . . "Definitive radiochemotherapy with weekly cisplatin in patients with head and neck cancer; single institution outcome analysis"@en . . "Dvo\u0159\u00E1k, J." . . "Kube\u0161, Ji\u0159\u00ED" . "7"^^ . "RIV/00064211:_____/12:#0000213" . . . "RIV/00064211:_____/12:#0000213!RIV14-MZ0-00064211" . . "Definitive radiochemotherapy with weekly cisplatin in patients with head and neck cancer; single institution outcome analysis" . "7"^^ . . "Definitive radiochemotherapy with weekly cisplatin in patients with head and neck cancer; single institution outcome analysis"@en . "[2E07233154E7]" . "000309793000010" . . . "I" . . . . "129859" . "17" . "3" . "P\u00E1la, Miloslav" . "Hole\u010Dkov\u00E1, Petra" . "Podle\u0161\u00E1k, Tom\u00E1\u0161" . . "V\u00EDtek, Pavel" . "radiochemotherapy; head and neck cancer; concomitant chemoradiotherapy; cisplatin"@en . . . "Purpose: The objective of this study was to evaluate the feasibility, toxicity and efficacy of definitive radiochemotherapy with weekly cisplatin in head and neck cancer in a single institutional setting. Methods: Previously untreated patients with stage II-IV head and neck cancer were included. Radiotherapy consisted of 70 Gy/7 weeks/35 fractions. All patients received concurrent cisplatin 40 mg/m(2) weekly Results: Between 2/2002 and 8/2009, 148 consecutive patients (WHO <= 2, male to female ratio 6/1, median age 56 years) were treated. The mean follow-up was 40 months. Tumors of the oropharynx were the most frequent (46%) and stage IV predominated (80%). Eighty-nine percent of the patients had received the full radiation treatment as planned. Omission of weekly cisplatin occurred frequently, mainly because of hematological toxicity. Only 64% of the patients completed at least 5 cycles of chemotherapy. Grade 3/4 mucosal toxicity developed in 32% of the patients. The late toxicities were acceptable: 74% of the patients were able to eat solid food during the 1st post-treatment year 4 patients were not able to swallow at all during the 1st post-treatment year, requiring thus permanent feeding tube. Five cases of osteora-dionecrosis of the mandible were reported. Three-year overall survival, locoregional control, time to progression and disease free survival were 34, 60, 52 and 29%, respectively. Conclusion: Definitive radiochemotherapy with weekly cisplatin was toxic, with high rate of morbidity and mortality in this patient population. Five weekly cycles of 40 mg/m(2) cisplatin seem to be the dose limit for most patients. Three-year survival was significantly reduced despite the promising high initial response and locoregional control." . . "Definitive radiochemotherapy with weekly cisplatin in patients with head and neck cancer; single institution outcome analysis" . "GR - \u0158eck\u00E1 republika" . "Odr\u00E1\u017Eka, Karel" . . "Journal of BUON" . . "4"^^ .